Drugs / Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants
Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06349031 | Apr → Sep 2024 | constipation disorder, functional colonic disease, intestinal impaction | Institute of Medical Sciences and SUM Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06349031 ↗ |
| Modality | Other / unclassified | “These are non-absorbable polymers, that create an osmotic gradient in the intestinal lumen leading to fluid retention which in turn softens and loosens the stool.” NCT06349031 ↗ |